Page 45 - MEMOCiberdem014-ENG

Most relevant scientific articles
• morro m., teiCHenne J., Jiménez V., kratzer r., marletta s., maGGioni l. et al . Pancreatic transduc- tion by helper-dependent adenoviral vectors via intraductal delivery . Human Gene Therapy . 2014;25(9):824-836 .
• CHurlaud G., Jiménez V., ruBerte J., amadoudJi zin m., FourCade G., Gottrand G. et al . Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infec- tion, vaccination and cancer . Clinical Immunology . 2014;151(2):114-126 .
• BoGdanoV P., Corraliza l., Villena J.a., CarValHo a.r., GarCía-arumi J., ramos d. et al . The db/db mouse: A useful model for the study of diabetic retinal neurodegeneration . PLoS ONE . 2014;9(5) .
• mendes-JorGe l., ramos d., ValenCa a., lóPez-luPPo m., Pires V.m.r., Catita J. et al . L-ferritin binding to Scara5: A new iron traffic pathway potentially implicated in retinopathy . PLoS ONE . 2014;9(9) .
Highlights
Institution: Universidad Autónoma de Barcelona Contact: Centro de Biotecnología Animal y Terapia Genética · Edificio H-Campus. Univ. Aut. Barcelona Phone: (+34) 93 581 41 82 · E.mail: [email protected] · Website: http://www.uab.cat
In 2014 we have been participating in the project “Unravelling of novel factors capable of inducing browning of WAT in vivo” financed by the European Foundation for the Study of Diabetes (2013-2015) . In addition, our group is participating in the EU, Programme “Capacities”, “European infrastructure for phenotyping and archiving of model mammalian genomes (Infrafrontier-I3) (2013-2016)“ with the aim to implement research infrastructure that provides capacities and open access for the systemic phenotyping, archiving and distribution of mouse models to the biomedical research community . In 2014, 2 new projects in which we are involved have been launched . One is the EU COST action “Development of a European network for preclinical testing of interventions in mouse models of age and age-related diseases (MouseAGE)” . This COST Action, starting in 2014 and ending in 2018, aims to form a highly interactive and flexible European network, which will create a critical mass of scientists across disciplines, clinicians and industrial partners to reach consensus on ways to test preclinical interventions in aging mice . The other project is dedicated to “AAV-mediated gene therapy for the treatment of MPSIIID (Sanfilippo D)” financed by the Association Française contre les Myopathies (2014-2016) .
In addition, our group has been involved in 6 new patents (1-Adenoassociated virus vectors for the treatment of lysosomal storage disorders . 2- Adeno-associated viral vectors useful in therapy, 3- Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease, 4- Vectors virals per al tractament de la diabetis: AAV8-IGF1, 5-Telomerase reverse transcriptase-based therapies, 6-Telomerase reverse transcriptase-based therapies for treatment of conditions associated with myocardial infarction) .
www .ciberdem .org 45